These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 23999854)

  • 1. The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy.
    Kluth LA; Shariat SF; Kratzik C; Tagawa S; Sonpavde G; Rieken M; Scherr DS; Pummer K
    World J Urol; 2014 Jun; 32(3):669-76. PubMed ID: 23999854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?
    Tolkach Y; Joniau S; Van Poppel H
    BJU Int; 2013 Jun; 111(7):1021-30. PubMed ID: 23418666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer.
    Rick FG; Schally AV
    Urol Oncol; 2015 Jun; 33(6):270-4. PubMed ID: 25512159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
    Kirby RS; Fitzpatrick JM; Clarke N
    BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of LHRH antagonists in the treatment of prostate cancer.
    Crawford ED; Hou AH
    Oncology (Williston Park); 2009 Jun; 23(7):626-30. PubMed ID: 19626830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
    Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
    Pedraza R; Kwart AM
    Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degarelix: a new approach for the treatment of prostate cancer.
    Persson BE; Kold Olesen T; Jensen JK
    Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteinising hormone-releasing hormone antagonists in prostate cancer therapy.
    Msaouel P; Diamanti E; Tzanela M; Koutsilieris M
    Expert Opin Emerg Drugs; 2007 May; 12(2):285-99. PubMed ID: 17604502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developments in the control of testicular function.
    Swerdloff RS; Wang C; Bhasin S
    Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal therapy of prostate cancer.
    Debruyne F
    Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):4-9. PubMed ID: 12198632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
    Clinton TN; Woldu SL; Raj GV
    Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.
    Thomsen FB; Bosco C; Garmo H; Adolfsson J; Hammar N; Stattin P; Van Hemelrijck M
    Acta Oncol; 2019 Jan; 58(1):110-118. PubMed ID: 30375907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
    Crawford ED; Tombal B; Keane T; Boccardo F; Miller K; Shore N; Moul JW; Damber JE; Collette L; Persson BE
    Scand J Urol; 2018; 52(5-6):349-357. PubMed ID: 30624128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.